News Pfizer fears rough ride with NICE over breast cancer drug Concerns over NICE's treatment of add-on therapies.
News Janssen’s Imbruvica latest to gain NICE approval after price... Leukaemia drug latest cancer treatment to gain NICE approval
Views & Analysis Three NICE thresholds for cost-effectiveness: does that make... NICE wants a new, third threshold for rare disease drugs - but what's the evidence behind it?
Views & Analysis Pharma’s new ‘sensible pricing’ behind cancer drug approvals... A string of 'yes' decisions from NICE on cancer drugs - but what has changed?
News Price cut brings ‘breakthrough’ NICE approval of Perjeta NICE says price cut made approval possible, despite continuing uncertainty about benefits
News SCOTUS backs generic firm Hikma in skinny label dispute SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
